心脏骤停昏迷幸存者的氧合目标
该随机2×2析因试验纳入789例院外心脏骤停昏迷成人,1:1分配至限制性氧合目标(PaO2 9~10 kPa,即68~75 mm Hg)或宽松性氧合目标(PaO2 13~14 kPa,即98~105 mm Hg),同时分配至两种血压目标之一(另文报告)。主要终点为随机化后90天内全因死亡或出院时严重残疾或昏迷(CPC 3或4分)复合终点。限制性组主要终点事件126/394例(32.0%),宽松性组134/395例(33.9%),HR 0.95(95%CI 0.75~1.21),P=0.69,两组不良事件发生率相似。
要点
- 789例院外心脏骤停昏迷成人随机分配至限制性氧合目标(PaO2 9~10 kPa,68~75 mm Hg)或宽松性氧合目标(PaO2 13~14 kPa,98~105 mm Hg)。
- 主要复合终点(90天内全因死亡或出院时CPC 3或4分)发生率:限制性组32.0%(126/394)vs 宽松性组33.9%(134/395),HR 0.95(95%CI 0.75~1.21),P=0.69。
- 90天死亡:限制性组28.7%(113例)vs 宽松性组31.1%(123例)。
- 48小时神经元特异性烯醇化酶中位数:限制性组17 μg/L vs 宽松性组18 μg/L;两组不良事件发生率相似。
- 90天改良Rankin量表中位评分:限制性组2分 vs 宽松性组1分;CPC中位分类两组均为1;蒙特利尔认知评估中位评分两组均为27分。
适用人群与场景
- 院外心脏骤停后昏迷的成人患者,经复苏后接受机械通气。
处置流程与药物剂量
- 限制性氧合目标:动脉血氧分压(PaO2)9~10 kPa(68~75 mm Hg)。
- 宽松性氧合目标:动脉血氧分压(PaO2)13~14 kPa(98~105 mm Hg)。
研究设计与关键结果
- 随机2×2析因试验,789例院外心脏骤停昏迷成人,1:1分配至限制性氧合目标(PaO2 9~10 kPa)或宽松性氧合目标(PaO2 13~14 kPa),同时分配至两种血压目标之一(另文报告)。
- 主要终点为随机化后90天内全因死亡或出院时严重残疾或昏迷(CPC 3或4分)复合终点,以先发生者为准。
- 主要终点事件:限制性组126/394例(32.0%)vs 宽松性组134/395例(33.9%),HR 0.95(95%CI 0.75~1.21),P=0.69。
- 90天死亡:限制性组113例(28.7%)vs 宽松性组123例(31.1%)。
- CPC中位分类两组均为1;改良Rankin量表中位评分限制性组2分 vs 宽松性组1分;蒙特利尔认知评估中位评分两组均为27分。
- 48小时神经元特异性烯醇化酶中位水平:限制性组17 μg/L vs 宽松性组18 μg/L。
- 不良事件发生率两组相似。
证据类型、等级与局限
- 证据类型:随机对照试验(2×2析因设计)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于院外心脏骤停后昏迷的机械通气患者,采用限制性氧合目标(PaO2 9~10 kPa)或宽松性氧合目标(PaO2 13~14 kPa)在死亡或严重残疾或昏迷复合终点上结果相似。
指南或共识出处
- BOX试验(ClinicalTrials.gov注册号NCT03141099),由诺和诺德基金会资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The appropriate oxygenation target for mechanical ventilation in comatose survivors of out-of-hospital cardiac arrest is unknown.
METHODS: In this randomized trial with a 2-by-2 factorial design, we randomly assigned comatose adults with out-of-hospital cardiac arrest in a 1:1 ratio to either a restrictive oxygen target of a partial pressure of arterial oxygen (Pao2) of 9 to 10 kPa (68 to 75 mm Hg) or a liberal oxygen target of a Pao2 of 13 to 14 kPa (98 to 105 mm Hg); patients were also assigned to one of two blood-pressure targets (reported separately). The primary outcome was a composite of death from any cause or hospital discharge with severe disability or coma (Cerebral Performance Category [CPC] of 3 or 4; categories range from 1 to 5, with higher values indicating more severe disability), whichever occurred first within 90 days after randomization. Secondary outcomes were neuron-specific enolase levels at 48 hours, death from any cause, the score on the Montreal Cognitive Assessment (ranging from 0 to 30, with higher scores indicating better cognitive ability), the score on the modified Rankin scale (ranging from 0 to 6, with higher scores indicating greater disability), and the CPC at 90 days.
RESULTS: A total of 789 patients underwent randomization. A primary-outcome event occurred in 126 of 394 patients (32.0%) in the restrictive-target group and in 134 of 395 patients (33.9%) in the liberal-target group (hazard ratio, 0.95; 95% confidence interval, 0.75 to 1.21; P = 0.69). At 90 days, death had occurred in 113 patients (28.7%) in the restrictive-target group and in 123 (31.1%) in the liberal-target group. On the CPC, the median category was 1 in the two groups; on the modified Rankin scale, the median score was 2 in the restrictive-target group and 1 in the liberal-target group; and on the Montreal Cognitive Assessment, the median score was 27 in the two groups. At 48 hours, the median neuron-specific enolase level was 17 μg per liter in the restrictive-target group and 18 μg per liter in the liberal-target group. The incidence of adverse events was similar in the two groups.
CONCLUSIONS: Targeting of a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest resulted in a similar incidence of death or severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).
参考来源
- Schmidt H, Kjaergaard J, Hassager C, et al. Oxygen Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022. PMID: 36027567. doi:10.1056/NEJMoa2208686
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。